

http://www.nature.com/nature

This press release is copyright *Nature*. Its use is granted only for journalists and news media receiving it directly from *Nature*.

*** PLEASE DO NOT REDISTRIBUTE THIS DOCUMENT *** VOL.736 NO.7616 DATED 18 AUGUST 2016

EMBARGO:

1800 London time (BST) / 1300 US Eastern Time Wednesday 17 August 2016 0200 Japanese time / 0300 Australian Eastern Time Thursday 18 August 2016

Wire services' stories must always carry the embargo time at the head of each item, and may not be sent out more than 24 hours before that time.

Solely for the purpose of soliciting informed comment on *Nature* papers, you may show relevant parts of this document, and the papers to which it refers, to independent specialists – but you must ensure in advance that they understand and accept *Nature*'s embargo conditions.

Editorial contacts: While the best contacts for stories will always be the authors themselves, in some cases the *Nature* editor who handled the paper will be available for comment if an author is unobtainable. Feel free to get in touch with *Nature*'s press contacts in London, New York and Tokyo (as listed at the end of this release) with any general editorial inquiry.

Warning: This document, and the papers to which it refers, may contain sensitive or confidential information not yet disclosed to the public. Using, sharing or disclosing this information to others in connection with securities dealing or trading may be a violation of insider trading under the laws of several countries, including, but not limited to, the UK Financial Services and Markets Act 2000 and the US Securities Exchange Act of 1934, each of which may be subject to penalties and imprisonment.

The research papers are available on the Nature press site at: http://press.nature.com

 PDFs of News & Views, News Features, Correspondence and Comment pieces will be available by 1400 London time / 0900 US Eastern Time on the Monday before publication

PICTURES: While we are happy for images from *Nature* to be reproduced for the purposes of contemporaneous news reporting, you must also seek permission from the copyright holder (if named) or author of the research paper in question (if not).

HYPE: We take great care not to hype the papers mentioned on our press releases, but are sometimes accused of doing so. If you ever consider that a story has been hyped, please do not hesitate to contact us at press@nature.com, citing the specific example.

PLEASE CITE *NATURE* AS THE SOURCE OF THE FOLLOWING ITEMS. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO http://www.nature.com/nature

Genetics: An in-depth insight into human genetic variation (N&V)

DOI: 10.1038/nature19057

DOI: 10.1038/gim.2016.90 DOI: 10.1038/ng.3638

An in-depth analysis of the exomes (protein-coding regions) of the human genome provides the most comprehensive catalogue of genetic variation in these regions to date. It is thought that the study, reported in this week's *Nature*, will improve efforts to identify clinically relevant genetic variation for human disease.

As part of the Exome Aggregation Consortium (ExAC), Daniel MacArthur and colleagues sequenced the exomes of 60,706 individuals of diverse geographic ancestry, including European, African, South Asian, East Asian and Latino populations. They identified around 7.4 million genetic variants, providing unprecedented resolution into low-frequency protein-coding variants in human populations. The authors analyse this dataset to characterize patterns of genetic variation worldwide, bringing resolution that has not been possible on smaller datasets of genetic variation. The density of genetic variation has allowed for resolution of multiple sequence variants at the same site (multiallelic variants), while the size of the dataset allows some of the first findings on mutational recurrence — rare mutations arising independently during the history of the populations.

ExAC provides an openly accessible reference database that has already proved useful as a clinical tool for evaluating purported Mendelian (single-gene) disease-causing variants, some of which are implausibly common in the population. The authors analysed 192 such variants reported in prior studies and found that only nine had sufficient data to support disease association. In a separate paper published in *Genetics in Medicine*, Roddy Walsh and colleagues evaluated genetic variation in one of the most common serious Mendelian disorders, cardiomyopathy (disease of the heart muscle). Their findings suggest that many genes and variants previously associated with a given cardiomyopathy are likely spurious, but that variant interpretation can now be significantly improved using ExAC.

In a third paper, published in *Nature Genetics*, Douglas Ruderfer and colleagues analyse rare copy number variation (a type of genome structural variation) within the ExAC dataset.

Previous research efforts have sought to catalogue genetic variation within the exome, but ExAC is the largest, most thorough initiative of its kind. In an accompanying News & Views, Jay Shendure concludes: "ExAC is both a technical and political achievement, requiring wrangling not only of data but also of investigators, consents and more from 14 studies — most of which were directed at the genetics of various common diseases."

Please link to the scientific papers in online versions of your report (the URLs will go live after the embargo ends):

http://dx.doi.org/10.1038/nature19057 http://dx.doi.org/10.1038/gim.2016.90 http://dx.doi.org/10.1038/ng.3638